ACTRN12618001938291已完成未知
Phase II of Objective Assessment of Visual Performance Using Optokinetic Nystagmus in Young Children
Objective Acuity (Australia) Pty Ltd0 个研究点目标入组 20 人开始时间: 2018年11月29日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 3 Years 至 5 Years（—）
- 性别
- All
入选标准
- •Children will be eligible for inclusion if they meet the following criteria:
- •Aged 3-5 years old (36-71 months at the time of registration)
- •Have parent(s)/guardian(s) willing to provide informed consent
- •Have no known visual impairment (VA < 6/24 or LogMar 0.6))
排除标准
- •Potentially eligible children will be excluded if they have any of the criteria below:
- •Infantile nystagmus syndrome
- •Eye muscle surgery within the past 6 months
- •Current eye disease
- •Developmental delay (known or suspected)
- •Systemic disease or syndrome
- •Visual impairment <6/24 or LogMar 0.6
研究者
相似试验
招募中
不适用
sing eye movements to measure vision in childreAnisometropiaStrabismusACTRN12617000338369niversity of Auckland120
招募中
不适用
Development of a new system for evaluating visual function in diabetic retinopathy using EvokeDxdiabetic retinopathyJPRN-UMIN000040444St Luke's International University100
尚未招募
Unknown
Screening and Confirmation for Selected Visual problems and Assessing Effect of Community Volunteers in Facilitating Seeking Care for Visual problems among the Elders in A Selected Urban Primary Health Care Setting, Puducherry- A StudyCTRI/2023/10/059071Jawaharlal Institute of Postgraduate Medical Education and Research
招募中
不适用
Behavior of multiple sclerosis patients' view in computer useC10.114.375.500Multiple SclerosisRBR-4m6zdhEscola de Artes, Ciências e Humanidade da Universidade São Paulo
进行中（未招募）
1 期
Imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT (Imaging of the membranair receptor HER2 with the tracer zirconium 89 trastuzumab) and an early FDG-PET/CT response (early metabolic assessment) to identify patients with HER-2 positive invasive carcinoma of the breast with locally recurrent (not amenable to resection with curative intent) or metastatic disease unlikely to benefit from a novel anti-HER2 therapy: T-DM1EUCTR2011-005437-39-BEJules Bordet Institute105